Fox Run Management L.L.C. Invests $136,000 in Emergent Biosolutions Inc. $EBS

Key Points

• Fox Run Management L.L.C. has acquired 28,020 shares of Emergent Biosolutions Inc., valued at approximately $136,000, during the 1st quarter.
• Institutional investors own 78.40% of Emergent Biosolutions, with several firms increasing their stakes significantly, including a 198.9% increase by Prescott Group Capital Management.
• Emergent Biosolutions reported $0.16 earnings per share (EPS) for the last quarter, exceeding analysts' expectations of a loss, but noted a revenue shortfall compared to forecasts.

Fox Run Management L.L.C. acquired a new stake in Emergent Biosolutions Inc. (NYSE:EBS - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 28,020 shares of the biopharmaceutical company's stock, valued at approximately $136,000. Fox Run Management L.L.C. owned approximately 0.05% of Emergent Biosolutions at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the business. EP Wealth Advisors LLC purchased a new stake in shares of Emergent Biosolutions during the 4th quarter worth approximately $110,000. Alpine Global Management LLC purchased a new stake in shares of Emergent Biosolutions during the 4th quarter worth approximately $112,000. SBI Securities Co. Ltd. boosted its stake in shares of Emergent Biosolutions by 95.1% during the 1st quarter. SBI Securities Co. Ltd. now owns 12,951 shares of the biopharmaceutical company's stock worth $63,000 after acquiring an additional 6,313 shares in the last quarter. Balyasny Asset Management L.P. purchased a new stake in shares of Emergent Biosolutions during the 4th quarter worth approximately $127,000. Finally, Corton Capital Inc. purchased a new stake in shares of Emergent Biosolutions during the 1st quarter worth approximately $70,000. Hedge funds and other institutional investors own 78.40% of the company's stock.

Emergent Biosolutions Price Performance

Shares of Emergent Biosolutions stock traded down $0.14 during trading on Wednesday, hitting $8.58. 655,267 shares of the company were exchanged, compared to its average volume of 1,486,013. The company has a quick ratio of 3.00, a current ratio of 5.66 and a debt-to-equity ratio of 1.25. Emergent Biosolutions Inc. has a fifty-two week low of $4.02 and a fifty-two week high of $12.73. The stock has a market capitalization of $457.48 million, a price-to-earnings ratio of 3.50 and a beta of 1.97. The firm has a 50 day moving average price of $7.37 and a 200 day moving average price of $6.50.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.16 earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.42. The company had revenue of $140.90 million during the quarter, compared to the consensus estimate of $148.55 million. Emergent Biosolutions had a return on equity of 24.63% and a net margin of 16.38%. On average, equities analysts expect that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen lowered Emergent Biosolutions from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $14.33.

Insider Buying and Selling at Emergent Biosolutions

In other Emergent Biosolutions news, Director Kathryn C. Zoon sold 7,086 shares of the business's stock in a transaction on Friday, August 15th. The stock was sold at an average price of $8.87, for a total value of $62,852.82. Following the completion of the transaction, the director directly owned 71,799 shares in the company, valued at approximately $636,857.13. The trade was a 8.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Donald W. Degolyer sold 7,844 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $8.65, for a total value of $67,850.60. Following the completion of the transaction, the director owned 137,659 shares of the company's stock, valued at $1,190,750.35. This trade represents a 5.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.20% of the company's stock.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.